Clinical Trials Browser

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05312216 2023-01-26

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Phase 2 Unknown

25 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Phase 2 Unknown

70 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Phase 2 Unknown

40 enrolled

Gastrointestinal

Resectable Biliary Tract Cancer

NCT04893252 2022-11-30

Vactosertib and Durvalumab in Gastric Cancer

Phase 2 Unknown

55 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

65 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT04961918 2021-07-14

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Unknown

36 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04851132 2021-06-22

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Phase NA Unknown

33 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04293419 2021-06-21

DUREC

Phase 2 Unknown

58 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04913480 2021-06-04

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Phase 2 Unknown

37 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04517227 2021-05-03

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Phase NA Unknown

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Phase 2 Unknown

40 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04621370 2020-11-09

PRIME-RT

Phase 2 Unknown

48 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04443322 2020-09-22

Dulect2020-1

Phase NA Unknown

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02520453 2019-12-09

Adjuvant Durvalumab for Esophageal Cancer

Phase 2 Unknown

86 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04054518 2019-08-13

DESC

Phase 2 Unknown

22 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Clinical Trials

RICE

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

PANDORA

VIVA

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Vactosertib and Durvalumab in Gastric Cancer

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

DUREC

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

PRIME-RT

Dulect2020-1

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Adjuvant Durvalumab for Esophageal Cancer

DESC